Key Decisions in HIV Care: Considering the Use of Proviral DNA Genotyping to Inform ART Choice

In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced.

Listen as he gives his perspectives on:

• US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotyping
• US Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resistance
• Study 380-4030 on outcomes with bictegravir- and dolutegravir-based ART in patients with preexisting nucleos(t)ide reverse-transcriptase inhibitor resistance
• The BRAAVE 2020 study on switching to bictegravir/emtricitabine/tenofovir alafenamide in Black persons with HIV, some of whom had baseline ART resistance
• Between-class ART switches with underlying resistance
• Susceptibility of tenofovir disoproxil fumarate and abacavir with thymidine analogue mutations

Presenter:

John D. Baxter, MD
Professor of Medicine
Division of Infectious Diseases
Department of Pathology
Cooper Medical School of Rowan University
Head, Division of Infectious Diseases
Cooper University Health Care
Camden, New Jersey

Follow along with the slides at:
https://bit.ly/3HmkSLc

See the entire program at: 
https://bit.ly/3fOl0XX

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.